Showing results (721-730 of 6,300) with videos related to

Sort By:
Pageof 630
Diabetes, Obesity & Metabolism|May 14, 2014
The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetesT Heise, M Larbig, S Patel, et al.
Diabetes, Obesity & Metabolism|October 1, 2016
Could metformin be used in patients with diabetes and advanced chronic kidney disease?Tahseen A Chowdhury, Danushan Srirathan, Georgi Abraham, et al.
Diabetes, Obesity & Metabolism|October 4, 2016
The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetesUlrich Rohde, Cecilie A Federspiel, Peter Vilmann, et al.
Diabetes, Obesity & Metabolism|April 8, 2014
Evidence for inhibitory autocrine effects of proinsulin C-peptide on pancreatic β-cell function and insulin secretionA M McKillop, M T Ng, Y H A Abdel-Wahab, et al.
Diabetes, Obesity & Metabolism|April 30, 2014
Mitochondrial target of thiazolidinedionesJ R Colca, W G McDonald, R F Kletzien
Diabetes, Obesity & Metabolism|January 31, 2014
Characterization of the metabolic effects of irisin on skeletal muscle in vitroR A Vaughan, N P Gannon, M A Barberena, et al.
Diabetes, Obesity & Metabolism|March 24, 2017
Dual CCR2/CCR5 antagonist treatment attenuates adipose inflammation, but not microvascular complications in ob/ob micePhillipe D O'Brien, Lucy M Hinder, Sebastian D Parlee, et al.
Diabetes, Obesity & Metabolism|April 24, 2012
Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysisK Gooßen, S Gräber
Diabetes, Obesity & Metabolism|April 24, 2012
Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cellsJ Liang, K K Leung, S Y Lam, et al.
Diabetes, Obesity & Metabolism|October 10, 2014
Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trialS A Ross, A E Caballero, S Del Prato, et al.
Pageof 630